Gynecological Cancer Drugs Market Industry Players, Key Trends Insights, Market Size, Estimation, By Aroma Therapeutic Associates, Application And Regional Forecast To 2026
SEATTLE, April 01, 2021, (PHARMIWEB) — Gynecological cancer is defined as uncontrolled growth and spread of abnormal cells in the female reproductive organs such as cervix, uterus, ovaries, vagina, and vulva. Furthermore, several factors responsible for occurrence of gynecological cancer includes infection from virus known as HPV or Human Papillomavirus. Moreover, factors such as infertility, obesity, mutations, early start of menstruation or late start of menopause also leads to gynecological cancer.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1744
Gynecological cancer can be treated with different medication, therapies, surgeries, or chemotherapy. Treatment of gynecological cancer also depends upon type and stage of the cancer. There are different types of this cancer such as uterine, ovarian cancer, vaginal cancer, vulvar cancer, and cervical cancer. Each gynecologic cancer is unique with different signs and symptoms, different risk factors, and different prevention strategies.
However, high cost of drug development, threat of failure, and adverse effects of cancer drug therapy are the factors that are expected to restrain growth of the gynecological cancer drug market over the forecast period. Moreover, advancements in cancer drug research and advent of personalized medicine approach are expected to provide lucrative opportunities for market players during the forecast period, which is further expected to drive market growth.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/39utMrq
Gynecological Cancer Drugs Market Dynamics
Moreover, in order to cater to increasing demand for gynecological cancer drugs, pharmaceutical and biotechnological companies are focusing on research and development to launch new gynecological cancer drugs in the market. Furthermore, some generic manufactures are also focusing on manufacturing patent off drugs in the generic form, for the treatment of this cancer. For instance, Dr Reddy’s Laboratories based in India, in May 2017, received the U.S. Food and Drug Administration approval to launch Doxorubicin Hydrochloride Liposome injection in the U.S. market. This doxorubicin hydrochloride liposome is a therapeutic equivalent generic version of Doxil, which is a chemotherapy drug used in the treatment of certain cancer such as ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.
Furthermore, in 2017, U.S. FDA also approved Zejula (niraparib), which is targeted therapy drug for women with some types of ovarian, fallopian tube, or peritoneal cancers. It is also approved for women with relapsed cancer after chemotherapy. American Cancer Society, as of March 2018 has funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer.
Increasing prevalence of gynecological cancers is expected to be a major factor for growth of the market. According to American Cancer Society, endometrium cancer, a type of cervical cancer, was estimated to be the most common cancer of the female reproductive organs. Furthermore, around 47,130 new cases of endometrial cancer was diagnosed in the U.S. in 2012, and about 8,010 women were reported to die from endometrial cancer. Moreover, according to American Cancer Society, ovarian cancer is the eighth most common cancer among women and in 2012, around 22,280 new cases of ovarian cancer were diagnosed in the U.S., which is expected to support growth of the gynecological cancer drugs market over the forecast period.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1744
Gynecological Cancer Drugs Market – Regional Insights
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share in the gynecological cancer drugs market, followed by Europe market in 2016. This is attributed to increasing prevalence of cervical cancer in the U.S. For instance, according to the Center for Disease Control and Prevention in 2014, 12,578 women in the U.S. ware diagnosed with cervical cancer and 4,115 women died from cervical cancer. Therefore, this is expected to drive demand for gynecological cancer drugs in North America.
Furthermore, Asia Pacific is estimated to grow at faster rate due to large population pool and government initiatives to create awareness regarding gynecological cancer. For instance, the Indian government published an operational framework for the country’s first national screening program, in 2016, where there will be mandatory screening for oral, breast, and cervical cancer in people over the age of 30 in 100 districts of India.
Gynecological Cancer Drugs Market – Competitive Analysis
Manufactures are involved in research and development, to enter the gynecological cancer drugs market. For instance, Oasmia Pharmaceutical AB, in May 2018, announced results from the completed phase III study with Apealea for treatment of ovarian cancer.
Major players operating in the market include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1744
Gynecological Cancer Drugs Market Taxonomy:
By Therapeutic Modality:
- Targeted Therapy
- Hormonal Therapy
- Uterine Cancer
- Ovarian Cancer
- Vaginal & Vulvar Cancer
- Cervical Cancer
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Gynecological Cancer Drugs Market Research Report
Section 1: Global Gynecological Cancer Drugs Industry Overview
Section 2: Global Economic Impact on Gynecological Cancer Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Gynecological Cancer Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Gynecological Cancer Drugs Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire